MEN1 and acute myeloid leukemia: Another study showed that the Menin inhibitor Revumenib inhibited the proliferation and survival of primary NUP08 fusion protein-positive AML cells and inhibited numerous NUP fusion protein target genes, such as MEIS1 and CDK6 [130].